Focused On-demand Library for Dolichol-phosphate mannosyltransferase subunit 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O60762

UPID:

DPM1_HUMAN

Alternative names:

Dolichol-phosphate mannose synthase subunit 1; Dolichyl-phosphate beta-D-mannosyltransferase subunit 1; Mannose-P-dolichol synthase subunit 1

Alternative UPACC:

O60762; O15157; Q6IB78; Q96HK0

Background:

Dolichol-phosphate mannosyltransferase subunit 1, also known as Dolichol-phosphate mannose synthase subunit 1, plays a pivotal role in glycoprotein biosynthesis. It is responsible for transferring mannose from GDP-mannose to dolichol monophosphate, a critical step in the formation of dolichol phosphate mannose. This process is essential for N-glycosylation, glycosyl phosphatidylinositol membrane anchoring, and O-mannosylation of proteins, highlighting its significance in cellular functions and development.

Therapeutic significance:

The protein's involvement in Congenital disorder of glycosylation 1E, a condition characterized by a wide array of clinical features including defects in nervous system development and immunodeficiency, underscores its therapeutic potential. Understanding the role of Dolichol-phosphate mannosyltransferase subunit 1 could open doors to potential therapeutic strategies for treating this multisystem disorder.